TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02144168

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotics-free enteral formula
Description: Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics containing enteral formula
Description: Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
Study: NCT02937896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: 40 micrograms Nasal Desmopressin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30mg intravenous Ketorolac.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 1cc intravenous Normal Saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 4 puffs nasal Normal Saline.
Study: NCT01255761

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol (CZP)
Description: 400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol (CZP)
Description: 400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52
Study: NCT02792647

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01
Description: Administered orally
Study: NCT01313624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZLI administered via nebulizer three times daily
Study: NCT02715427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery
Study: NCT00644878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
Study: NCT02101268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
Study: NCT01438762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient information and education
Description: All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information, education and physiotherapy
Description: Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class.
Study: NCT02785445

Intervention type: DEVICE
Group type: OTHER
Intervention: Dip.io Home Based Dipstick Analyzer
Description: First intervention (assigned to the All participants arm).

Intervention type: DEVICE
Group type: OTHER
Intervention: ACON U500 Mission® U500 Urine Analyzer
Description: Second intervention (assigned to the All participants arm).
Study: NCT00774423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: 50 mg per day during 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: 50 mg per day during 24 months
Study: NCT03602222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile web training LGBT mental health
Description: Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person training LGBT mental health
Description: In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
Study: NCT03889054

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program
Description: The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~1. Plan of action in an exacerbation.~2. Education related to COPD.~3. Information on pharmacological medication.~4. Management of the exacerbation.~5. Management of stress and / or anxiety.~6. Nutritional recommendations.~7. Physical exercise recommendations.~8. Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts.
Study: NCT01013740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine
Study: NCT01270698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-130
Description: IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
Study: NCT03949712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Static Magnetic Field Stimulation (tSMS)
Description: tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Static Magnetic Field Stimulation (tSMS)
Description: tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Static Magnetic Field Stimulation (tSMS)
Description: Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
Study: NCT00548847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-α-2b
Description: Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
Study: NCT04933981

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab for SARS-CoV-2
Description: in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
Study: NCT02460536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification treatment (ABMT)
Description: Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure only +ABMT
Description: Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention training only +ABMT
Description: Attention training via repeated trials of a dot-probe task using non-emotional stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Identical discrimination task including a single non-emotional stimulus in each trial.
Study: NCT01006889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
Study: NCT03232034

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Citrate
Description: 1000 mg calcium as calcium citrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Mineral Supplement
Description: Milk Minerals containing 1000 mg calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Mineral Supplement
Description: Milk Minerals containing 1000 mg calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate
Description: 50 g whey protein hydrolysate
Study: NCT03641456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
Study: NCT01642095

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03245177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 antibody

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60-66 Gy in 30-33 fractions, 2 Gy per fraction
Study: NCT02138656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic
Description: Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic
Description: Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Standard Care
Description: Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Standard Care
Description: Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Best Standard Care
Description: Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard Care
Description: Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
Study: NCT04582747

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)
Description: Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively.
Study: NCT01551069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine (Z0188)
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT02620956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nebulizing with heliox and oxygen
Description: Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nebulizing with heliox and oxygen
Description: Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
Study: NCT01773876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
Study: NCT00296010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide 50 mg/day orally continuously for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
Study: NCT03569475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran extended-release oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral capsules
Study: NCT04311047

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Description: Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
Study: NCT03679897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine solution
Description: ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine solution
Description: ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
Study: NCT04364685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on soft-sand
Description: The participants are required to walking on sand for 30 minutes. Walking is self-paced.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking on Levelled Surface
Description: The Participants will be require to walk on the firm surface for 30 minutes. The participants would decide the pace of walking.
Study: NCT01062971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide-timolol-brimonidine
Description: Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide-timolol-brimonidine
Description: Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
Study: NCT03896074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered intravenously at 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered intravenously at 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab intravenously at 15 mg/kg every 3 weeks
Study: NCT01430208

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resectoscopy
Description: hysteroscopy for myomas G0 and/or polyps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resectoscopy
Description: hysteroscopy for myomas G0 and/or polyps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resectoscopy
Description: hysteroscopy for myomas G0 and/or polyps
Study: NCT02478385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care in a specially designed labour room
Description: Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive care in a specially designed labour room
Description: Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
Study: NCT03862261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated pediatric TB services
Description: pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~* Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~* Improvement of diagnosis capacities and their integration in all levels of care and all services.
Study: NCT02870712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture of perineum
Description: suture of the tear to obtain hemostasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture of perineum
Description: suture of the tear to obtain hemostasis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemostatis by digital compression
Description: Digital compression of the tear to obtain hemostasis